The Cooper Companies, Inc. $COO Shares Acquired by Quantitative Investment Management LLC

Quantitative Investment Management LLC increased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 111.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,024 shares of the medical device company’s stock after purchasing an additional 19,014 shares during the quarter. Quantitative Investment Management LLC’s holdings in Cooper Companies were worth $2,469,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after buying an additional 7,363 shares in the last quarter. Campbell & CO Investment Adviser LLC lifted its position in shares of Cooper Companies by 29.8% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 12,487 shares of the medical device company’s stock valued at $889,000 after acquiring an additional 2,866 shares during the period. ProShare Advisors LLC boosted its stake in shares of Cooper Companies by 12.6% during the 2nd quarter. ProShare Advisors LLC now owns 35,635 shares of the medical device company’s stock worth $2,536,000 after acquiring an additional 3,990 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Cooper Companies by 36.6% during the 2nd quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock worth $68,000 after acquiring an additional 257 shares in the last quarter. Finally, KBC Group NV grew its holdings in shares of Cooper Companies by 17.3% in the 2nd quarter. KBC Group NV now owns 295,590 shares of the medical device company’s stock worth $21,034,000 after acquiring an additional 43,622 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Trading Down 3.0%

Shares of Cooper Companies stock opened at $71.52 on Friday. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $89.83. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.34 and a quick ratio of 0.79. The business has a 50 day moving average price of $81.45 and a 200 day moving average price of $75.97. The company has a market capitalization of $13.95 billion, a P/E ratio of 35.41, a P/E/G ratio of 1.90 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.07. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.02 billion. Cooper Companies had a return on equity of 10.34% and a net margin of 9.67%.Cooper Companies’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.92 EPS. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on COO. Wall Street Zen raised Cooper Companies from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Mizuho set a $100.00 target price on Cooper Companies and gave the stock an “outperform” rating in a research report on Friday, December 5th. Weiss Ratings raised Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. Piper Sandler restated an “overweight” rating and issued a $94.00 price target (up from $83.00) on shares of Cooper Companies in a research report on Friday, December 5th. Finally, Citigroup cut their price target on Cooper Companies from $88.00 to $87.00 and set a “neutral” rating for the company in a research note on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $90.79.

Insiders Place Their Bets

In related news, insider Holly R. Sheffield acquired 1,230 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were acquired at an average price of $80.75 per share, with a total value of $99,322.50. Following the completion of the purchase, the insider directly owned 39,052 shares in the company, valued at approximately $3,153,449. The trade was a 3.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Maria Rivas acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were bought at an average price of $82.13 per share, with a total value of $82,130.00. Following the transaction, the director owned 11,141 shares in the company, valued at $915,010.33. This represents a 9.86% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders bought 16,014 shares of company stock valued at $1,304,416. Insiders own 2.08% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.